Nishio Kazuaki, Shigemitsu Meiei, Kodama Yusuke, Itoh Seiji, Konno Noburu, Satoh Ryuji, Katagiri Takashi, Kobayashi Youichi
Third Department of Internal Medicine, School of Medicine, Showa University, Tokyo, Japan.
J Cardiometab Syndr. 2008 Fall;3(4):200-4. doi: 10.1111/j.1559-4572.2008.00019.x.
The aim of this study was to evaluate the effect of pioglitazone on nitric oxide in patients with type 2 diabetes and coronary artery disease. Twenty-seven patients with coronary artery disease and diabetes mellitus who had received coronary stenting were eligible for the study. They were assigned to the no insulin resistance (NIR) group, the insulin resistance (IR) group, and the pioglitazone group (30 mg once a day). Endothelial nitric oxide synthase (eNOS), inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNF-alpha), interleukin-6, leptin, and adiponectin were measured. In the pioglitazone group, eNOS, iNOS, and leptin were significantly lower and adiponectin was significantly higher than those in the IR group. Stepwise multiple regression analyses showed that eNOS correlated with TNF-alpha and iNOS correlated with leptin and TNF-alpha. Leptin was the strongest predictor of iNOS. Treatment with pioglitazone significantly reduced eNOS and iNOS by improving adipocytokine levels.
本研究旨在评估吡格列酮对2型糖尿病合并冠状动脉疾病患者一氧化氮的影响。27例接受冠状动脉支架置入术的冠状动脉疾病合并糖尿病患者符合研究条件。他们被分为无胰岛素抵抗（NIR）组、胰岛素抵抗（IR）组和吡格列酮组（每日一次，30毫克）。检测内皮型一氧化氮合酶（eNOS）、诱导型一氧化氮合酶（iNOS）、肿瘤坏死因子α（TNF-α）、白细胞介素-6、瘦素和脂联素。在吡格列酮组中，eNOS、iNOS和瘦素显著低于IR组，脂联素显著高于IR组。逐步多元回归分析显示，eNOS与TNF-α相关，iNOS与瘦素和TNF-α相关。瘦素是iNOS的最强预测因子。吡格列酮治疗通过改善脂肪细胞因子水平显著降低eNOS和iNOS。
